Hepatic metabolism of MK-0457, a potent Aurora kinase inhibitor: Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1447-1451

  Ballard, J E ^a   Prueksaritanont, T ^a   Tang, C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE INHIBITOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES COMPARISON;

ALGORITHMS; ANIMALS; ANTIBODIES, BLOCKING; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DOGS; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; LIVER; MACACA FASCICULARIS; MONOAMINE OXIDASE; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; RATS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 34548093338     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015438     Document Type: Article

References (19)

1. Bosch TM, Meijerman I, Beijnen JH, and Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253-285.
2. Bourrie M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
4. Cashman JR (2002) Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3:325-339.
5. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, and Freedman J (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500-502.
6. Grothusen A, Hardt J, Bräutigam L, Lang D, and Böcker R (1996) A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Arch Toxicol 71:64-71.
7. Haining RL, Hunter AP, Sadeque AJM, Philpot RM, and Rettie AE (1997) Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. Drug Metab Dispos 25:790-797.
8. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267.
9. Jiang N, Wang X, Yang Y, and Dai W (2006) Advances in mitotic inhibitors for cancer treatment. Mini Rev Med Chem 6:885-895.
10. Katayama H, Brinkley WR, and Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451-464.
11. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
12. Li AP, Rogue MA, Beck DJ, and Kaminski DL (1992) Isolation and culturing of hepatocytes from human liver. J Tissue Cult Method 139-146.
13. Lin JH and Lu AYH (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
14. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, and Shou M (2001) Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368-374.
15. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW (1994) Selective biotransformation of taxol to 6-α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
16. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochrome P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
17. Shimada T (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
18. Shimada T, Tsumura F, and Yamazaki H (1999) Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274-1280.
19. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, et al. (2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17-36.